News

Oral cancer survival lower with positive margins, public insurance


 

FROM JAMA OTOLARYNGOLOGY–HEAD & NECK SURGERY

References

In patients who underwent surgical treatment for stage I or II oral cavity squamous cell cancer, positive tumor margin, the use of radiation or chemotherapy, treatment in a nonacademic facility, and having public health insurance were significantly associated with lower 5-year survival rates, according to a retrospective analysis published online in the JAMA Otolaryngology–Head & Neck Surgery.

The findings suggest that some factors associated with lower 5-year survival rates “may be targets for quality improvement efforts,” wrote Alexander L. Luryi of Yale University, New Haven, Conn., and colleagues.

Seventy percent of 6,830 patients who underwent surgery for stage I or II oral cavity squamous cell cancer (OCSCC) from 2003 to 2006 survived 5 years, according to information from the National Cancer Data Base.

Multivariate analysis showed higher survival rates were significantly associated with neck dissection (hazard ratio, 0.85; P = .003). Lower survival rates were significantly associated with radiation therapy (HR, 1.31; P < .001), chemotherapy (HR, 1.34; P = .03), nonprivate insurance (HR Medicaid, 1.96; HR Medicare, 1.45; P < .001), and nonacademic treatment facility (HR, 1.13; P = .03).

Care at academic centers compared with nonacademic centers was associated with improved survival, possibly due to health care provider expertise, the study authors noted (JAMA Otolaryngol. Head Neck Surg. 2015 May 14 [doi:10.1001/jamaoto.2015.0719]).

Survival rates were lower in patients treated at nonacademic cancer centers, but multivariate analysis showed no association between facility-based case volume and survival. Patients insured through Medicaid and Medicare had significantly lower 5-year survival rates (P < .001 for both). That finding may be the result of inconsistent treatment and follow-up, the investigators said, or worse baseline health among that patient population.

Controversy exists over the relationship between positive margins and outcomes, and the implications for aggressiveness of surgery. The study found positive margins were significantly associated with poorer outcomes, the researchers noted, which supports the use of aggressive surgery in early OCSCC to achieve negative margins.

Radiation and chemotherapy were linked to worse outcomes, and those therapies were possibly indicators of less aggressive resection in localized disease. The analysis could not adjust for potential confounding effects of perineural and lymphovascular invasion, because the information was not recorded in the National Cancer Data Base.

The study indicated a positive impact by neck dissection on survival. Patients with occult neck disease who underwent neck dissection likely would have been restaged to stage III or higher and removed from the early stage sample, the authors explained, which would account for higher survival rates for those remaining. Prospective trials are needed to determine the role of elective neck dissection in early OCSCC, the researchers added.

The William U. Gardner Memorial Research Fund at Yale University supported the study. Dr. Luryi and coauthors reported having no disclosures.

Recommended Reading

SCORPION: Interval debulking is safer in advanced ovarian cancer
MDedge Hematology and Oncology
Sentinel node mapping adequately detects nodal spread of endometrial cancer
MDedge Hematology and Oncology
Oophorectomy improves survival after breast cancer in BRCA1 carriers
MDedge Hematology and Oncology
ELCC: NSCLC mutation testing highlights ctDNA’s limitations
MDedge Hematology and Oncology
ASA: Tumors glow green in new ‘optical biopsy’ technique
MDedge Hematology and Oncology
Biomarker correlates with pancreatic cancer severity
MDedge Hematology and Oncology
ELCC: Urine tumor DNA shows high testing promise
MDedge Hematology and Oncology
ASA: Radiation lowers local recurrence risk for DCIS patients with close or positive margins
MDedge Hematology and Oncology
ASA: Electroporation shows promise for locally advanced pancreatic cancer
MDedge Hematology and Oncology
Neoadjuvant chemotherapy for triple negative breast cancer improves conservation
MDedge Hematology and Oncology